Compare McKesson Corporation (MCK) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nucor Corporation — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while Nucor Corporation trades at $233.58 (market cap $52.55B). The key difference: McKesson Corporation is the larger of the two by market cap, and Nucor Corporation pays the higher dividend (0.97%). Which is the better fit depends on your goals.
| MCK | NUE | |
|---|---|---|
Market Cap | $97.35B | $52.55B |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $266.35 |
52-Week Low | $659.01 | $131.78 |
Enterprise Value | $101.98B | $57.19B |
Dividend Yield | 0.39% | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Nucor (NUE) trades at $231.86, down 2.01% today, with a bullish technical signal from moving averages and a consensus analyst price target of $263.11. Recent earnings beat expectations in Q1 2026 with EPS of $3.23 versus $2.82 forecast, though Q4 2025 missed. Revenue trends show recovery from $30.7B in 2024 to $32.5B in 2025, with net income margin improving to 6.82% in 2026 projections. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% in 2025 and recently announced a joint venture to support AI power infrastructure.
Outlook remains positive driven by higher steel prices and strategic expansions, but risks include cyclical demand weakness and volatile cash flows. Analyst sentiment is bullish with 62.5% buy ratings, supporting potential upside from current levels, though investors should monitor execution on Q2 2026 earnings expected at $4.45 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
